Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? | Zendy

Aravinda M. de Silva | Zendy; Eva Harris | Zendy

Open Access

Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?

Author(s) -

Aravinda M. de Silva,

Eva Harris

Publication year - 2017

Publication title -

cold spring harbor perspectives in biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.011

H-Index - 173

ISSN - 1943-0264

DOI - 10.1101/cshperspect.a029371

Subject(s) - dengue fever , dengue vaccine , dengue virus , biology , virology , vaccination , antibody dependent enhancement , flavivirus , japanese encephalitis , serotype , disease , immunity , immunology , virus , yellow fever , vaccine efficacy , encephalitis , immune system , medicine , pathology

Dengue virus (DENV) is the most common arthropod-borne viral disease of humans. Although effective vaccines exist against other flaviviral diseases like yellow fever and Japanese encephalitis, dengue vaccine development is complicated by the presence of four virus serotypes and the possibility of partial immunity enhancing dengue disease severity. Several live attenuated dengue vaccines are being tested in human clinical trials. Initial results are mixed, with variable efficacy depending on DENV serotype and previous DENV exposure. Here, we highlight recent discoveries about the human antibody response to DENV and propose guidelines for advancing development of safe and effective dengue vaccines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research